At a glance
ClinicalIndex Comparison RecordN/ACompleted· 547 enrolled
Drug / intervention
etorocoxib +1 moredrug
Likely dose
etorocoxib 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacoepidemiological Study on the Use of Arcoxia® Under Actual Conditions of Use in France
In Brief
An observational study evaluating etorocoxib and celecoxib for Osteoarthritis. Completed, enrolled 547 participants.
Detailed Summary
This postmarketing study will examine the use of etoricoxib (Arcoxia®) in routine clinical practice in France as well as the use of celecoxib (Celebrex®).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis
Countries--
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 2012
Enrollment StartJun 2012
Primary CompletionMar 2015
TodayJul 2026
First PostedApr 6, 2012
Enrollment StartJun 1, 2012
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 14.2 years ago
Interventions
etorocoxibdrug
Administered as 30 mg or 60 mg oral film-coated tablets
celecoxibdrug
Administered as 100 mg or 200 mg oral hard capsules